Vesalio's Strategic Hire Signals Major Push in Clot-Busting Market

PLANO, TX – July 14, 2026 – In a move that signals a significant escalation of its commercial ambitions, privately held medical device innovator Vesalio has appointed Greg Cook as its new Chief Commercial Officer (CCO). While executive appointments are routine, this one is a clear strategic play. By bringing in a seasoned commercial leader from a global giant like Philips, Vesalio is signaling its intent to aggressively scale its operations and capture a larger share of the burgeoning multi-billion-dollar thrombectomy market.

Cook will now helm Vesalio's entire commercial apparatus—from strategy and market development to sales and marketing—as the company aims to expand its proprietary thrombectomy platform across the challenging neurovascular, coronary, and peripheral vascular markets. The appointment is less about filling a role and more about acquiring a catalyst for growth at a pivotal moment for the company.

The Commercial Catalyst for a Scale-Up Phase

Greg Cook is not a typical sales leader; he is a market builder with a documented history of transforming innovative technology into commercial success. With over 20 years in the medical device sector, his most recent tenure at Philips Image Guided Therapy Devices is particularly telling. As Senior Vice President of Sales, he spearheaded the U.S. commercialization of the VeriSight™ intracardiac echocardiography platform, growing the business by more than eightfold and building the entire supporting organization from the ground up.

This experience is precisely what Vesalio needs as it transitions from a company with proven technology to a dominant commercial force. As one industry analyst noted, "Hiring a CCO of this caliber is a classic move for a well-funded, high-potential company looking to shift from innovation-led growth to market-led dominance. It's about building the machinery to scale."

In the official announcement, Vesalio's CEO, Steve Rybka, underscored this strategic alignment. "Greg brings the commercial leadership, market development expertise, and physician relationships that align with Vesalio's strategic priorities," he stated. "His experience building commercial organizations and introducing innovative technologies to treat vascular disease will be a valuable asset as we expand our thrombectomy platform."

Cook's background demonstrates a deep understanding of how to navigate the complex sales cycles and clinical adoption hurdles inherent in the medical device industry. His leadership at Philips also included managing the Cardiac Lead Management sales organization, giving him crucial experience across the diverse vascular intervention landscape that Vesalio targets.

Navigating a Crowded and Complex Battlefield

Cook's challenge—and Vesalio's opportunity—lies in a thrombectomy market that is both lucrative and fiercely competitive. Valued at over $1.7 billion in 2025, the global market for these clot-removing devices is projected to exceed $3 billion by the early 2030s, driven by an aging population and the rising prevalence of thromboembolic diseases like stroke and peripheral artery disease.

Vesalio competes against entrenched industry giants like Stryker, Medtronic, and Penumbra in the neurovascular space. However, the company has carved out a distinct position with its unique technology. In the coronary market, Vesalio's enVast™ system stands out as the "first and only clot retriever specifically cleared for mechanical thrombectomy in the cardiac circulation." This is a significant differentiator, as major clinical guidelines have downgraded recommendations for routine aspiration thrombectomy, leaving a critical unmet need for managing large clot burdens in heart attack patients.

In the peripheral vascular market, Vesalio's pVasc® system contends with offerings from leaders like Inari Medical. Here, its advantage lies in a low-profile design capable of navigating small, complex arteries, particularly below the knee—a frequent challenge in treating patients with severe peripheral artery disease. Cook's primary task will be to translate these technological differentiators into tangible market share across all three segments.

The Innovation Engine: Technology as the Core Differentiator

At the heart of Vesalio's strategy is its proprietary Drop Zone® technology, an integrated feature across its NeVa®, enVast™, and pVasc® platforms. Unlike some conventional devices that may struggle with certain clot types, the Drop Zone is engineered to effectively capture and remove the full spectrum of thrombi—from soft, fresh clots to dense, organized ones that are notoriously difficult to dislodge. This capability is critical for achieving high "first-pass success," a key clinical metric linked to better patient outcomes and reduced procedural complications.

This focus on handling so-called "recalcitrant clots" directly addresses a significant unmet need in stroke intervention, where up to 20% of cases involve thrombi that resist conventional removal methods. By providing a more reliable solution, Vesalio aims to become an indispensable tool for interventional physicians.

Further demonstrating its strategic vision, Vesalio has recently secured FDA 510(k) clearances for aspiration catheters for both peripheral and neurovascular applications. This move indicates a deliberate strategy to build a comprehensive "thrombectomy ecosystem" that combines its best-in-class mechanical retrievers with aspiration technology, offering physicians a complete and integrated toolkit. With its products having already treated over 19,000 patients in more than 60 countries, Vesalio has a strong clinical foundation upon which Cook can now build a commercial empire.

Primed for Growth: Capital, Infrastructure, and Vision

Vesalio's appointment of a CCO is the capstone on a series of strategic moves designed to prime the company for explosive growth. The privately held firm is well-capitalized, having raised a total of $52.8 million in funding from key investors like Solas BioVentures and Orlando Health Ventures. This financial backing has fueled its R&D, supported U.S. clinical trials, and enabled its international expansion.

In 2024, the company relocated its headquarters from Nashville to Plano, Texas, a strategic decision to tap into the Dallas area's robust medical device ecosystem and skilled workforce. This move, combined with the recent hiring of a new CFO and now a CCO, demonstrates a methodical approach to building the corporate infrastructure required for scaling.

Joining the company, Cook expressed his alignment with this vision. "I am excited to join Vesalio and work alongside a talented team committed to advancing thrombectomy management," he said. "Vesalio's commitment to clinical innovation and physician partnership creates a strong foundation for continued growth, and I look forward to expanding access to technologies that improve patient outcomes."

With a powerful technology platform, a strong financial foundation, and now a proven commercial leader at the helm, Vesalio is making it clear that it is no longer just an innovator to watch, but a competitor ready to challenge the status quo in vascular intervention.